Xylocaine Injection, Solution
NDC Package 70518-4152-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Xylocaine (lidocaine hydrochloride, epinephrine bitartrate) injection is xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. This formulation utilizes a injection, solution delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-4152 and is authorized under FDA application NDA006488.

Identification & Billing

NDC Package Code
70518-4152-2
Package Description
25 VIAL, MULTI-DOSE in 1 TRAY / 50 mL in 1 VIAL, MULTI-DOSE (70518-4152-3)
Product Code
11-Digit Billing Format
70518415202
RxNorm Crosswalk
  • RxCUI: 1010751 - lidocaine HCl 1 % / EPINEPHrine 1:100,000 Injectable Solution
  • RxCUI: 1010751 - epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution
  • RxCUI: 1010751 - epinephrine (as epinephrine bitartrate) 1:100,000 / lidocaine hydrochloride 1 % Injectable Solution
  • RxCUI: 1010755 - Xylocaine 1 % / EPINEPHrine 1:100,000 Injectable Solution
  • RxCUI: 1010755 - epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine with Epinephrine]

Clinical Specifications

Proprietary Name
Xylocaine
Non-Proprietary Name
Lidocaine Hydrochloride, Epinephrine Bitartrate
Substance Name
Epinephrine Bitartrate; Lidocaine Hydrochloride Anhydrous
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Infiltration - Administration that results in substances passing into tissue spaces or into cells.
  • Perineural - Administration surrounding a nerve or nerves.
Usage Information
Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

Regulatory & Marketing

Labeler Name
Remedyrepack Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA006488
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-31-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70518-4152). Click a package code to view its specific billing and regulatory data.

25 VIAL, MULTI-DOSE in 1 TRAY / 20 mL in 1 VIAL, MULTI-DOSE (70518-4152-0)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70518-4152-2 identifies a specific commercial package of 25 vial, multi-dose in 1 tray / 50 ml in 1 vial, multi-dose (70518-4152-3) of Xylocaine, a human prescription drug labeled by Remedyrepack Inc.. This injection, solution is formulated for infiltration; perineural use and contains epinephrine bitartrate; lidocaine hydrochloride anhydrous as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on July 31, 2024. The current certification is valid through December 31, 2026.

How is this Remedyrepack Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518415202. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70518-4152-2
11-Digit CMS (5-4-2)
70518-4152-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.